Ginkgo Results Presentation Deck
Adjusted EBITDA Reconciliation (Unaudited)
In millions of USD
Net loss attributable to Ginkgo Bioworks Holdings, Inc. stockholders
Interest (income) expense, net
Income tax (benefit) provision
Depreciation and amortization
EBITDA
Stock-based compensation 1
Loss on equity method investments
Loss (gain) on investments
Change in fair value of warrant liabilities
Gain on deconsolidation of subsidiary
Merger and acquisition related expenses
In-process research and development 4
Other 5
Adjusted EBITDA
2
3
Three Months Ended June 30,
2022
2021
($668.8)
($1.7)
($0.0)
$9.6
($660.9)
$607.3
$10.0
$38.7
($23.5)
$0.0
$2.7
$1.6
$0.9
($23.3)
($53.9)
$0.5
($0.4)
$7.2
($46.7)
$14.5
$3.8
($2.8)
$0.0
$0.0
$0.0
$0.0
($6.4)
($37.5)
Six Months Ended June 30,
2021
($127.5)
$1.0
($0.6)
$12.8
2022
($1,259.3)
($1.3)
($0.2)
$19.1
($1,241.7)
$1,266.3
$30.2
$38.2
($108.5)
($15.9)
$6.6
$1.6
$0.3
($22.9)
($114.4)
$14.6
$31.2
($15.4)
$0.0
$0.0
$0.0
$0.0
($4.8)
($88.7)
(1)
For the three and six months ended June 30, 2022, includes employer payroll taxes of $0.8 million and $7.0 million, respectively.
(2) Represents losses on equity method investments under the hypothetical liquidation at book value method, net of losses attributable to non-controlling interests.
(3) Represents transaction and integration costs directly related to mergers and acquisitions including (i) due diligence, legal and other professional fees associated with acquisitions and (ii) the fair value adjustments to contingent consideration liabilities resulting from acquisitions. In
the second quarter of 2022, we redefined Adjusted EBITDA to exclude the impact of merger and acquisition related expenses. We elected to recast our previous first quarter 2022 Adjusted EBITDA calculation to exclude these costs and conform to the new presentation.
(4) Represents acquired intangible assets expensed to research and development associated with a business acquisition.
(5) For the three and six months ended June 30, 2022, includes change in fair value of Access Bio Convertible Notes. For the three and six months ended June 30, 2021, includes change in fair value of Access Bio Convertible Notes and gain related to a settlement payment from
Amyris.
36
Property of Ginkgo Bioworks
Q2 2022 UPDATE & BUSINESS REVIEWView entire presentation